257 results on '"van Duin Mark"'
Search Results
2. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
3. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
4. Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial
5. P804: PLASMA CELL LEUKEMIA-LIKE TRANSCRIPTOME OF BONE MARROW PLASMA CELLS AND CIRCULATING TUMOR CELL LEVELS IN PERIPHERAL BLOOD COMPLEMENTARILY DEFINE HIGH-RISK IN NEWLY DIAGNOSED MULTIPLE MYELOMA
6. P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)
7. Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment?
8. Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
9. Supplementary Table 3 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
10. Supplemental data from Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients
11. Supplementary Table 4 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
12. Supplementary Figures from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
13. Supplementary Table 2 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
14. Supplementary Table 1 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
15. An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich microenvironment in multiple myeloma
16. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
17. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System
18. Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes
19. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
20. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
21. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile
22. P-062: MAF translocations are enriched in high-risk NDMM patients with elevated levels of circulating tumor cells suggesting a genetic basis for the aggressive disease course
23. OAB-029: Single-cell transcriptomic analysis reveals reduction of cytotoxic NK cells in a subset of newly diagnosed multiple myeloma patients impacting outcome after daratumumab therapy
24. P-082: Stromal cell - neutrophil interactions are driving a pro tumor environment in multiple myeloma
25. Treatment emergent peripheral neuropathy in the CASSIOPEIA trial
26. Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study
27. Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment?
28. VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma
29. P-080: Single-cell transcriptomic analysis of bone marrow NK cells reveals loss of activated cytotoxic NK cells in Multiple Myeloma
30. P-069: Inflammasome-primed neutrophils maintain a pro-tumor microenvironment in Multiple Myeloma
31. Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
32. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
33. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
34. V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
35. P-388 An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich tumor-supportive bone marrow environment in multiple myeloma patients
36. Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.
37. VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma.
38. Analytical Validation of SKY92 for the Identification of High-Risk Multiple Myeloma
39. Search for multiple myeloma risk factors using Mendelian randomization
40. Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma
41. Prognostic and Predictive Performance of SKY92 Combined with R-ISS in Elderly Multiple Myeloma Patients in The Hovon-87/NMSG-18 Study
42. The Role of EXT1 in Nonhereditary Osteochondroma: Identification of Homozygous Deletions
43. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
44. Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups-a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial
45. Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells
46. Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial
47. Cancer-selective targeting of the NF-?B survival pathway with GADD45ß/MKK7 inhibitors
48. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis
49. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy
50. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.